Investigating the clinical use of 13-valent pneumococcal conjugate vaccine (Prevenar) in childhood acute lymphoblastic leukaemia.

Trial Profile

Investigating the clinical use of 13-valent pneumococcal conjugate vaccine (Prevenar) in childhood acute lymphoblastic leukaemia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms PCV13 in ALL
  • Most Recent Events

    • 30 Jan 2014 Accrual to date is 87% according to United Kingdom Clinical Research Network.
    • 06 Dec 2013 Accrual to date is 85% according to United Kingdom Clinical Research Network.
    • 23 Nov 2013 Accrual to date is 84% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top